India, Aug. 13 -- Altimmune Inc. (ALT), a late clinical-stage biopharmaceutical company, on Wednesday announced financial results for the second quarter, noting a mild increase in loss owing to increased operating expenses.
The company is developing Pemvidutide, an investigational peptide that acts as a glucagon/GLP-1 dual agonist to reduce liver fat, fibrosis, and inflammation. The drug is being evaluated in trials for alcohol use disorder (AUD), alcohol-associated liver disease (ALD), and metabolic dysfunction-associated steatohepatitis (MASH).
Q2 Financial Readout:
The company reported a net loss of $22.82 million or $0.12 per share, marginally higher than the net loss of $22.15 million or $0.27 per share in 2025.
This may be attribu...